Immunotherapy company Stellar Biotechnologies Inc (Nasdaq:SBOT) stated on Tuesday that it recorded a net loss of USD1.41m (USD0.26 per basic share) for the three months ended 31 December 2018.
This is compared with a net loss of USD1.40m (USD0.93 per basic share) for the first quarter of the prior fiscal year.
Total revenues of USD0.05m were generated for the three months ended 31 December 2018, up by USD0.03m over the revenues USD0.02m for the same period last year primarily due to increased sales of higher value, clinical-grade KLH products.
Research and development expenses of USD0.47m were recorded for the three months ended 31 December 2018, a decline by USD0.16m from the R&D of USD0.63m for the same period last year, which was primarily due to a decrease in contracted research services and materials.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva